Δημοσιεύτηκε στισ 13 Αυγούστου, 202316 Αυγούστου, 2023 από adminThe Patent N-bromotaurine solutions and emulsions against abnormal cells Kyriakopoulos September 15, 2 uspto.report/patents/NASCO AD BIOTECHNOLOGY LABORATORY/Patent 16/079,997 U.S. patent number 10,772,855 [Application Number 16/079,997] was granted by the patent office on 2020-09-15 for n-bromotaurine solutions and emulsions against abnormal cells. The grantee listed for this patent is NASCO AD BIOTECHNOLOGY LABORATORY. Invention is credited to Antonios Kyriakopoulos. United States Patent 10,772,855 Kyriakopoulos September 15, 2020 N-bromotaurine solutions and emulsions against abnormal cellsAbstract In a method of producing aqueous solutions of N-bromotaurine (Taurine Bromanine, NBrT) with taurine with latter addition of NaOBr, and emulsions of these solutions with Stable Produced Olive Oil (S.P.O.O.), so to use against hyper-proliferative and abnormally differentiating cells of human and mammalian origin. In addition, due to the hyper-proliferation of keratinocytes in psoriatic skin, the methodology and subsequent use of the aqueous solutions and emulsions derived from this invention, containing NBrT and taurine, and S.P.O.O. against the lesions of psoriasis. With the method of this invention, the solutions derived and applied on cells in vitro beneficially provide maximization of NBrT anti-proliferative properties on abnormally differentiating and hyper-proliferating cells of human and mammalian origin by restoring NBrT anti-proliferative activity in a solution, whilst leaving unaffected the proliferation of normally dividing human fibroblasts. The use of NBrT/taurine solutions in psoriasis optimally comprises the simultaneous use of S.P.O.O. by concurrent mixing to make an emulsion. S.P.O.O. is derived from a patented physical refinement of olive oil [GR 1008334(B)] and is mixed with N-bromotaurine/taurine solutions to produce an active emulsion, and thereafter to derive ointments, creams, lotions, as medicinal preparations to treat psoriasis and Herpes Zoster dermatoses. Beneficially, when S.P.O.O. is utilized to make an emulsion with NBrT/taurine aqueous solutions and applied on psoriatic lesions coupled with NaOBr latter addition this shortens to half the time period for psoriasis lesions regression and minimizes side effects on dermal tissue as compared to the NBrT aqueous solution application on psoriatic lesions. Inventors: Kyriakopoulos; Antonios (Pireus, GR) Applicant: Name City State Country Type NASCO AD BIOTECHNOLOGY LABORATORY Pireus N/A GR Family ID: 58267140 Appl. No.: 16/079,997 Filed: February 17, 2017 PCT Filed: February 17, 2017 PCT No.: PCT/GR2017/000007 371(c)(1),(2),(4) Date: August 25, 2018 PCT Pub. No.: WO2017/149331 PCT Pub. Date: September 08, 2017 Prior Publication Data Document Identifier Publication Date US 20190060260 A1 Feb 28, 2019 Foreign Application Priority Data Mar 1, 2016 [GR] 20160100072 Current U.S. Class: 1/1 Current CPC Class: A61K 9/0014 (20130101); A61K 31/185 (20130101); A61K 47/36 (20130101); A61P 17/06 (20180101); A61K 9/08 (20130101); A61P 31/22 (20180101); A61P 17/00 (20180101); A61K 47/44 (20130101); A61K 9/107 (20130101); A61K 9/06 (20130101); A61K 31/185 (20130101); A61K 2300/00 (20130101) Current International Class: A61K 31/185 (20060101); A61P 17/06 (20060101); A61K 9/08 (20060101); A61K 9/107 (20060101); A61P 31/22 (20060101); A61P 17/00 (20060101); A61K 9/70 (20060101); A61K 47/44 (20170101); A61K 47/36 (20060101); A61K 9/00 (20060101); A61K 9/06 (20060101) References Cited [Referenced By] U.S. Patent Documents 2004/0214891 October 2004 Marcinkiewicz Primary Examiner: Klinkel; Kortney L.Attorney, Agent or Firm: Zigouris; James O. Claims The invention claimed is:1. A method for treating a condition presenting with hyper-proliferating and/or abnormally proliferating cells in a patient in need thereof, comprising topically applying an emulsion comprising taurine, N-bromotaurine (NBrT) and oil and separately applying a solution of NaOBr topically, and wherein the condition to be treated is selected from the group consisting of psoriasis, cancer, and herpes zoster.2. The method of claim 1, wherein the ratio of NBrT to taurine is 1:5.